These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 24848756)

  • 1. Luseogliflozin: first global approval.
    Markham A; Elkinson S
    Drugs; 2014 Jun; 74(8):945-50. PubMed ID: 24848756
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ipragliflozin: first global approval.
    Poole RM; Dungo RT
    Drugs; 2014 Apr; 74(5):611-7. PubMed ID: 24668021
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tofogliflozin: first global approval.
    Poole RM; Prossler JE
    Drugs; 2014 Jun; 74(8):939-44. PubMed ID: 24848755
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of Reduced Renal Function on the Glucose-Lowering Effects of Luseogliflozin, a Selective SGLT2 Inhibitor, Assessed by Continuous Glucose Monitoring in Japanese Patients with Type 2 Diabetes Mellitus.
    Jinnouchi H; Nozaki K; Watase H; Omiya H; Sakai S; Samukawa Y
    Adv Ther; 2016 Mar; 33(3):460-79. PubMed ID: 26846284
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sodium glucose co-transporter 2 inhibitor luseogliflozin in the management of type 2 diabetes: a drug safety evaluation.
    Yabe D; Hamamoto Y; Seino Y; Kuwata H; Kurose T; Seino Y
    Expert Opin Drug Saf; 2017 Oct; 16(10):1211-1218. PubMed ID: 28741382
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics, Pharmacodynamics, and Safety of Luseogliflozin in Japanese Patients with Type 2 Diabetes Mellitus: A Randomized, Single-blind, Placebo-controlled Trial.
    Sasaki T; Seino Y; Fukatsu A; Ubukata M; Sakai S; Samukawa Y
    Adv Ther; 2015 Apr; 32(4):319-40. PubMed ID: 25855342
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of luseogliflozin on bone microarchitecture in older patients with type 2 diabetes: study protocol for a randomized controlled pilot trial using second-generation, high-resolution, peripheral quantitative computed tomography (HR-pQCT).
    Haraguchi A; Shigeno R; Horie I; Morimoto S; Ito A; Chiba K; Kawazoe Y; Tashiro S; Miyamoto J; Sato S; Yamamoto H; Osaki M; Kawakami A; Abiru N
    Trials; 2020 May; 21(1):379. PubMed ID: 32370806
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Luseogliflozin for the treatment of type 2 diabetes.
    Seino Y
    Expert Opin Pharmacother; 2014 Dec; 15(18):2741-9. PubMed ID: 25359155
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dose-finding study of luseogliflozin in Japanese patients with type 2 diabetes mellitus: a 12-week, randomized, double-blind, placebo-controlled, phase II study.
    Seino Y; Sasaki T; Fukatsu A; Ubukata M; Sakai S; Samukawa Y
    Curr Med Res Opin; 2014 Jul; 30(7):1231-44. PubMed ID: 24673496
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical implication of SGLT2 inhibitors in type 2 diabetes.
    Kim GW; Chung SH
    Arch Pharm Res; 2014 Aug; 37(8):957-66. PubMed ID: 24950857
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factors Influencing Change in Serum Uric Acid After Administration of the Sodium-Glucose Cotransporter 2 Inhibitor Luseogliflozin in Patients With Type 2 Diabetes Mellitus.
    Chino Y; Kuwabara M; Hisatome I
    J Clin Pharmacol; 2022 Mar; 62(3):366-375. PubMed ID: 34545949
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sodium-glucose cotransporter 2 inhibitor luseogliflozin improves glycaemic control, assessed by continuous glucose monitoring, even on a low-carbohydrate diet.
    Nishimura R; Omiya H; Sugio K; Ubukata M; Sakai S; Samukawa Y
    Diabetes Obes Metab; 2016 Jul; 18(7):702-6. PubMed ID: 26639943
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanism-Based Pharmacokinetic-Pharmacodynamic Modeling of Luseogliflozin, a Sodium Glucose Co-transporter 2 Inhibitor, in Japanese Patients with Type 2 Diabetes Mellitus.
    Samukawa Y; Mutoh M; Chen S; Mizui N
    Biol Pharm Bull; 2017; 40(8):1207-1218. PubMed ID: 28769002
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sodium-glucose co-transporter-2 inhibitor use and dietary carbohydrate intake in Japanese individuals with type 2 diabetes: A randomized, open-label, 3-arm parallel comparative, exploratory study.
    Yabe D; Iwasaki M; Kuwata H; Haraguchi T; Hamamoto Y; Kurose T; Sumita K; Yamazato H; Kanada S; Seino Y
    Diabetes Obes Metab; 2017 May; 19(5):739-743. PubMed ID: 27990776
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Substantial Effects of Luseogliflozin Revealed by Analyzing Responses to Postprandial Hyperglycemia: Post Hoc Subanalyses of a Randomized Controlled Study.
    Samukawa Y; Omiya H; Watase H; Nozaki K; Sakai S; Nishimura R
    Adv Ther; 2016 Jul; 33(7):1215-30. PubMed ID: 27255763
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Luseogliflozin and other sodium-glucose cotransporter 2 inhibitors: no enemy but time?
    Pafili K; Papanas N
    Expert Opin Pharmacother; 2015 Mar; 16(4):453-6. PubMed ID: 25605060
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [SGLT2 inhibitor (Luseogliflozin): a new mechanism for treating type 2 diabetes mellitus and therapeutic potential to prevent the progression of diabetic complications].
    Kojima N; Samukawa Y; Takahashi T
    Nihon Yakurigaku Zasshi; 2016; 148(5):253-258. PubMed ID: 27803438
    [No Abstract]   [Full Text] [Related]  

  • 18. Efficacy and Safety of the SGLT2 Inhibitor Luseogliflozin in Japanese Patients With Type 2 Diabetes Mellitus Stratified According to Baseline Body Mass Index: Pooled Analysis of Data From 52-Week Phase III Trials.
    Sakai S; Kaku K; Seino Y; Inagaki N; Haneda M; Sasaki T; Fukatsu A; Kakiuchi H; Samukawa Y
    Clin Ther; 2016 Apr; 38(4):843-862.e9. PubMed ID: 27021608
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fifty-two-week long-term clinical study of luseogliflozin as monotherapy in Japanese patients with type 2 diabetes mellitus inadequately controlled with diet and exercise.
    Seino Y; Kaku K; Inagaki N; Haneda M; Sasaki T; Fukatsu A; Ubukata M; Sakai S; Samukawa Y
    Endocr J; 2015; 62(7):593-603. PubMed ID: 25971406
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of a new SGLT2 inhibitor, luseogliflozin, on diabetic nephropathy in T2DN rats.
    Kojima N; Williams JM; Takahashi T; Miyata N; Roman RJ
    J Pharmacol Exp Ther; 2013 Jun; 345(3):464-72. PubMed ID: 23492941
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.